PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King

Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce O’Shaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King Abtract: Clinical Read More

FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer

Source: San Antonio Breast Cancer Symposium® Authors: Robert Maganini, Ellis Levine, Kent Hoskins, Sarah Thayer, Alfredo Santillan, Sung HoLee, Eduardo Dias, Regina Hampton, Eric Brow Title: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer Background: The advent of subtype-specific treatments, particularly hormone therapies Read More

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposium® Authors: Joyce O’Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigators’ Group Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More

Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data

Source:  San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Eric Brown, Jailan Elayoubi, Priyanka Sharma, Jayanthi Ramadurai, Laurie Matt-Amral, Alfredo Santillan, Sasha Strain, Philip Albaneze, Read More

Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition

Source:  San Antonio Breast Cancer Symposium® Authors:  Adam Brufsky, VK Gadi, Aisha Ahmed, Preethi John, Beth Seiling, Josien Haan6, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O’Shaughnessy, FLEX Investigators’ Group Title: Association of MammaPrint® With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase Read More

Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials

Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Pérez Tenorio, N.P. Tobin, B.A. Nordenskjöld, O. Stål, L. Esserman, L.J. Van't Veer, L.S. Lindström Title: Differential long-term benefit of 2-year adjuvant tamoxifen Read More

Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial

Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van ’t Veer, PhD; Elma Meershoek-Klein Kranenbarg, MS; Marjolijn Duijm-de Carpentier, BS; Cornelis J. H. Van de Velde, MD; Miranda Kleijn, PhD; Christa Dreezen, MS; Andrea R. Menicucci, PhD; William Audeh, MD; Gerrit-Jan Liefers, MD, PhD Title: Selection of Patients With Read More